BrainsWay (BWAY) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
18 Mar, 2026Executive summary
Q4 2025 revenue rose 27% year-over-year to $14.5 million, with full-year revenue also up 27% to $52.2 million, exceeding guidance and reaching record highs.
Achieved 10 consecutive quarters of profitability, driven by expanding margins, recurring revenue, and multi-year contracts.
Strategic partnerships, minority investments in five mental health networks, and collaboration with Valor Equity Partners are fueling growth and innovation.
International expansion and new care settings are targeted for future growth, with a focus on adolescent and accelerated MDD protocols.
Shipped 95 Deep TMS systems in Q4, bringing the installed base to approximately 1,700 worldwide.
Financial highlights
Gross profit for Q4 was $11.1 million (76% margin), up from $8.5 million (75%) year-over-year; full-year gross profit reached $39.4 million (75% margin).
Adjusted EBITDA for Q4 was $2.3 million (up 53% YoY); full-year adjusted EBITDA was $7 million (13% of revenue), up from $4.5 million.
Net income for Q4 was $2.9 million, up 90% YoY; full-year net income was $7.6 million, up 161% YoY.
Ended 2025 with $68 million in cash and cash equivalents, and no debt.
Operating income for Q4 was $1.9 million, up from $0.4 million; full-year operating income was $4.3 million.
Outlook and guidance
2026 revenue guidance is $66–68 million, representing 27–30% year-over-year growth.
Operating income expected at 13–14% of revenue; adjusted EBITDA guidance is $12–14 million, up 86–100% over 2025.
Recurring revenue expected to increase, driven by multi-year leases and high customer retention (93%).
Management anticipates continued profitability and positive cash flow.
Targeted operating expense growth below 15% as revenue expands.
Latest events from BrainsWay
- Q2 revenue up 28%, profitability sustained, and FDA expands Deep TMS use to age 86.BWAY
Q2 20242 Feb 2026 - Q3 revenue up 26%, profitability sustained, and guidance raised with new equity financing.BWAY
Q3 202415 Jan 2026 - Record revenue, profitability, and global expansion set stage for strong 2025 growth.BWAY
Q4 202426 Dec 2025 - Shelf registration enables up to $100M in flexible securities offerings to support growth and R&D.BWAY
Registration Filing16 Dec 2025 - Registration enables a major shareholder to resell up to 3.6 million ADSs, with potential dilution.BWAY
Registration Filing16 Dec 2025 - Strong growth, recurring revenue, and clinical innovation position the company for global expansion.BWAY
Investor Presentation2 Dec 2025 - Accelerated protocols, recurring revenue, and Deep TMS expansion drive breakout growth in 2026.BWAY
Analyst & Investor Day 20251 Dec 2025 - Q2 2025 revenue up 26% YoY, net profit $2M, and guidance raised on recurring growth.BWAY
Q2 202523 Nov 2025 - Q1 revenue up 27% with record profit growth, strong margins, and expanding clinical pipeline.BWAY
Q1 202521 Nov 2025